You are here


A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: 
Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Selumetinib in Combination with Sirolimus
Accrual Status: 
Overall Study Principal Investigator: 
AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Health System

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute

For more information about this trial and open sites: